PROM1 and familial pancreatic carcinoma: We assume that pancreatic CSCs characterized CD133 expression may have a survival advantage under unfavorable hypoxic conditions, since EMT has been demonstrated to contribute to drug resistance in pancreatic cancer [32,35].